Q-omics provides the consensus-scored EML5 profile across patient tissues and cancer cell-line models. EML5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, EML5 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, EML5 RNA expression shows 19,839 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, and THYM as cancer lineages where EML5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EML5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EML5 survival associations across molecular data types. EML5 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EML5 RNA expression–survival associations across cancer types. High EML5 expression shows unfavorable associations in BLCA, but favorable associations in HNSC, BRCA, LGG, PAAD and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for EML5 RNA expression.
This table summarizes EML5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for EML5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EML5 shows lower tumor expression in KIRC, THCA, COAD, BRCA and READ and higher tumor expression in HNSC. The HNSC box plot shows higher EML5 RNA expression in tumor versus normal tissue (log2 FC = +0.694, t-test p < 0.001).
This table shows molecular features associated with EML5 in patient tissues and cancer cell lines. In patient samples, EML5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, EML5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
